non-coding RNA
The company's adaptive low-resource testing technology requires no instrumentation and limited equipment, making it adaptable to settings without clinical lab infrastructure.
The firm recently published a study describing three assays for prostate cancer and reporting their sensitivity and specificity in case-control cohort.
Researchers have demonstrated that they can detect more miRNAs, as well as other small RNA molecules, by sequencing these samples rather than using microarrays.
The company hopes to launch its first clinical cancer test within the next year, after spending the last several years conducting validation studies.
Such an atlas could enable investigators to understand how genetic variants impact disease risk, define drug toxicities, improve therapies, and advance regenerative medicine.